Skip to main content

Catalyst Calendar

Scope

Wed, Sep 30, 2026

1 updates
QTTB
9:15 AM

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing -- --

Trial Results • Phase 2presentation Wed, Sep 30, 2026q32bio.com

Mon, Sep 21, 2026

1 updates
QTTB
9:15 AM

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata -- WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc.

Presentation / Abstract • Phase 2EADV poster presentation Wed, Sep 30, 2026, 7:00 AM CESTq32bio.com

Mon, Sep 14, 2026

1 updates

Tue, Sep 1, 2026

1 updates
QTTB
6:59 AM

Q32 Bio to Participate in Upcoming September Investor Conferences

WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) (" Q32 Bio "), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in

q32bio.com

Wed, Aug 5, 2026

1 updates
QTTB
6:59 AM

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA

Trial Results • Phase 2presentation Wed, Aug 5, 2026q32bio.com

Tue, Jul 14, 2026

1 updates

Mon, Jul 13, 2026

2 updates
QTTB
6:59 AM

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis -- -- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20

Trial Results • Phase 2Topline results Mon, Jul 13, 2026q32bio.com